{"id":"https://openalex.org/W2603383161","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19137","title":"A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti\u2013PD-L1 antibody, in combination with tremelimumab in subjects with advanced non\u2013small cell lung cancer.","display_name":"A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti\u2013PD-L1 antibody, in combination with tremelimumab in subjects with advanced non\u2013small cell lung cancer.","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W2603383161","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19137","mag":"2603383161"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.e19137","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19137","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19137","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Mary Colleen Pinder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Colleen Pinder","raw_affiliation_strings":["H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075877134","display_name":"Naiyer A. Rizvi","orcid":"https://orcid.org/0000-0002-1134-7494","observed_orcids":["https://orcid.org/0000-0002-1134-7494"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naiyer A. Rizvi","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028192791","display_name":"Sarah B. Goldberg","orcid":"https://orcid.org/0000-0002-0920-1381","observed_orcids":["https://orcid.org/0000-0002-0920-1381"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah B. Goldberg","raw_affiliation_strings":["Yale Cancer Center, Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052730435","display_name":"Ani Sarkis Balmanoukian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104507","display_name":"Angeles Clinic and Research Institute","ror":"https://ror.org/01ct2ab72","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834","https://openalex.org/I4210104507"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ani Sarkis Balmanoukian","raw_affiliation_strings":["The Angeles Clinic and Research Institute, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Angeles Clinic and Research Institute, Los Angeles, CA","institution_ids":["https://openalex.org/I4210104507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110048076","display_name":"Rajesh Narwal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rajesh Narwal","raw_affiliation_strings":["MedImmune, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MedImmune, Gaithersburg, MD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062235853","display_name":"Paul B. Robbins","orcid":"https://orcid.org/0000-0003-3704-4616","observed_orcids":["https://orcid.org/0000-0003-3704-4616"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul B. Robbins","raw_affiliation_strings":["MedImmune, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MedImmune, Gaithersburg, MD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073976995","display_name":"Gina D\u2019Angelo","orcid":"https://orcid.org/0000-0002-5327-086X","observed_orcids":["https://orcid.org/0000-0002-5327-086X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gina D'Angelo","raw_affiliation_strings":["MedImmune, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MedImmune, Gaithersburg, MD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008012629","display_name":"Andy Blake-Haskins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andy Blake-Haskins","raw_affiliation_strings":["MedImmune, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MedImmune, Gaithersburg, MD","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040663360","display_name":"Joyson Joseph Karakunnel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joyson Joseph Karakunnel","raw_affiliation_strings":["MedImmune, Gaithersburg, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MedImmune, Gaithersburg, MD","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046273815","display_name":"Scott Joseph Antonia","orcid":"https://orcid.org/0000-0002-6686-3824","observed_orcids":["https://orcid.org/0000-0002-6686-3824"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Joseph Antonia","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"e19137","last_page":"e19137"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.9660000205039978},{"id":"https://openalex.org/keywords/tremelimumab","display_name":"tremelimumab","score":0.9369999766349792},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9350000023841858},{"id":"https://openalex.org/keywords/anti-ctla-4-antibody","display_name":"anti-CTLA-4 antibody","score":0.9819999933242798},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8309999704360962},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.6669999957084656},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.9549999833106995},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8510000109672546},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.953000009059906},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6449999809265137},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9399999976158142},{"id":"https://openalex.org/keywords/elevated-amylase","display_name":"elevated amylase","score":0.7450000047683716},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6480000019073486},{"id":"https://openalex.org/keywords/immune-cell-phenotypes","display_name":"immune cell phenotypes","score":0.6370000243186951},{"id":"https://openalex.org/keywords/cytokine-profiling","display_name":"cytokine profiling","score":0.9800000190734863}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8989490270614624},{"id":"https://openalex.org/C2778650287","wikidata":"https://www.wikidata.org/wiki/Q7838098","display_name":"Tremelimumab","level":5,"score":0.7562853097915649},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6873576641082764},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5711103081703186},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5646764039993286},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.529128909111023},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5278013944625854},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.510943591594696},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4450739622116089},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.2896271347999573},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.2678983211517334},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.23370465636253357}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.e19137","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19137","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.e19137","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2294542576","https://openalex.org/W2679423891","https://openalex.org/W2525915488","https://openalex.org/W2598780875","https://openalex.org/W2441203743","https://openalex.org/W2940373053","https://openalex.org/W2188594974","https://openalex.org/W2185680666","https://openalex.org/W2474824510","https://openalex.org/W2587807204"],"abstract_inverted_index":{"e19137^":[0],"Background:":[1],"CTLA-4":[2,38],"and":[3,39,138,143,168,183,208,256,277,282,290,296],"PD-L1":[4,40],"are":[5,259],"critical,":[6],"non-redundant,":[7],"signals":[8,26],"responsible":[9],"for":[10],"controlling":[11],"T-cell":[12],"activation.":[13],"Clinical":[14,315],"trials":[15],"have":[16,199,224],"shown":[17],"the":[18,62,65,135,152,180],"therapeutic":[19],"utility":[20],"of":[21,24,36,103,141,193,234,294],"blocking":[22],"each":[23],"these":[25],"in":[27,33,47,59,61,72,76,94,109,125,151,202,311],"order":[28],"to":[29,302,313],"enhance":[30],"anti-tumor":[31],"immunity":[32],"a":[34,51,121,157,187,232,241],"proportion":[35],"patients.":[37],"targeting":[41],"agents":[42,67],"show":[43],"similar":[44],"monotherapy":[45,93],"activity":[46,90,140],"mice":[48,78],"implanted":[49],"with":[50,92,111,128,247],"Kras":[52],"mutant":[53],"cancer":[54,98],"cell":[55,96,229,286],"line.":[56],"When":[57],"used":[58],"combination":[60,84,110],"same":[63],"model,":[64],"2":[66,222,243],"showed":[68],"significant":[69],"synergy,":[70],"resulting":[71],"complete":[73],"tumor":[74,297],"regression":[75],"all":[77],"treated.":[79],"These":[80],"observations":[81],"suggest":[82],"that":[83],"therapy":[85],"may":[86,299],"generate":[87],"greater":[88],"antitumor":[89],"compared":[91],"non\u2013small":[95],"lung":[97],"(NSCLC).":[99],"The":[100,145,263,271],"safety":[101,182,265],"profile":[102,266],"MEDI4736":[104],"(M),":[105],"an":[106,114],"anti-PD-L1":[107],"antibody,":[108,116],"tremelimumab":[112],"(T),":[113],"anti-CTLA-4":[115],"is":[117,133,147,214],"being":[118,260],"explored":[119],"using":[120,156,186],"4-wk":[122],"dosing":[123],"interval":[124],"patients":[126],"(pts)":[127],"NSCLC.":[129],"Methods:":[130],"This":[131],"study":[132,146,272],"evaluating":[134],"safety,":[136],"pharmacodynamics,":[137],"preliminary":[139],"M":[142],"T.":[144],"currently":[148],"enrolling":[149],"pts":[150,198,217,223],"dose":[153,162,269],"escalation":[154],"phase":[155,164],"3+3":[158],"design.":[159,190],"A":[160],"subsequent":[161],"expansion":[163],"will":[165,175,273],"include":[166,240],"immunotherapy-naive":[167],"-pretreated":[169],"cohorts.":[170],"In":[171],"addition,":[172],"intermediate":[173],"doses":[174],"be":[176,300],"explored,":[177],"depending":[178],"on":[179],"observed":[181],"efficacy":[184],"profile,":[185],"modified":[188],"zone-based":[189],"Results:":[191],"As":[192],"January":[194],"10,":[195],"2013,":[196],"3":[197],"been":[200],"treated":[201],"Cohort":[203],"1":[204,209,226],"(3":[205],"mg/kg":[206,210],"[M]":[207],"[T]):":[211],"age":[212],"range":[213],"72\u201378":[215],"years;":[216],"had":[218],"1\u20133":[219],"prior":[220],"treatments;":[221],"adenocarcinoma,":[225],"has":[227],"squamous":[228],"carcinoma.":[230],"After":[231],"follow-up":[233],"8-10":[235],"wks,":[236],"related":[237],"adverse":[238],"events":[239],"grade":[242,249],"asymptomatic":[244],"elevated":[245],"amylase":[246],"no":[248],"3/4":[250],"or":[251],"dose-limiting":[252],"toxicities":[253],"reported.":[254],"Pharmacokinetic":[255],"pharmacodynamic":[257,278],"data":[258],"analyzed.":[261],"Conclusions:":[262],"current":[264],"supports":[267],"continued":[268],"escalation.":[270],"also":[274],"assess":[275],"pharmacokinetic":[276],"parameters,":[279],"including":[280],"serum":[281],"tissue":[283],"PDL1,":[284],"immune":[285],"phenotypes,":[287],"cytokine":[288],"profiling,":[289],"flow.":[291],"Pharmacogenomic":[292],"analysis":[293],"blood":[295],"samples":[298],"performed":[301],"examine":[303],"gene":[304],"expression":[305],"patterns":[306],"at":[307],"baseline":[308],"versus":[309],"changes":[310],"response":[312],"treatment.":[314],"trial":[316],"information:":[317],"NCT02000947.":[318]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2017-04-07T00:00:00"}